Skip navigation

Arecor Secures £6M Investment for the Clinical Development of its Diabetes Speciality Pharma Portfolio

10 September 2018

Cambridge, UK., 10 September 2018: Arecor Ltd (“the Company”), the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6.0 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products.

This £6.0 million equity investment into Arecor was led by leading UK institutional investors, Calculus Capital, Downing Ventures, and Albion Capital with significant participation from Arecor’s existing investors. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures.

Arecor’s next-generation diabetes product pipeline represents exciting new progress in the field of diabetes that will enable important new treatment regimens and offer greater control of blood glucose to diabetes patients, which is key to improving outcomes and quality of life. 

Dr Sarah Howell, Chief Executive Officer at Arecor, commented: “We are delighted to have secured the investment that we need to progress our lead diabetes programmes through the key stages of clinical development.  With diabetes reaching epidemic proportions worldwide and with close to half a billion people living with the condition today, the opportunity of advancing our diabetes products into human clinical trials and their potential to significantly improve the treatment of this debilitating disease, represents a very exciting and ground-breaking proposition”.

To read more about this news item click here:


For more information, please contact:
Arecor Limited
Dr Sarah Howell, Chief Executive
Tel: +44 (0) 1223 426 060

Dr Jan Jezek, Chief Scientific Officer
Tel: +44 (0) 1223 426 060
Peckwater PR (Arecor)

Tarquin Edwards
Tel: +44 (0) 7879 458 364